Concepedia

David R Huron

DR

Statistics

Publications

1

Citations

118

H-Index

1

Active since

2003

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

David R Huron is an author at Memorial Sloan Kettering Cancer Center specializing in kinase mutation-mediated resistance, pharmacology, and src family kinase inhibitors.

Publications per year

2003–2003

1

Publications

1

A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.

David R Huron, M. Gorre, Alan J. Kraker et al. · PubMed · 2003 · 118 citations

, , +15

1–1 of 1